Loading...

Purified anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
R4-6A2
  • R4-6A2
Compare all formats
Cat # Size Price Save
505801 50 µg ¥14,780
505802 500 µg ¥29,920
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA Capture - Quality tested
CyTOF® - Verified
IHC, WB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IFN-γ recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Zhang S, et al. 2017. Nature.. 10.1038/nature24283. PubMed
  2. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  3. Lin F, et al. 2019. Sci Adv. 5:eaax1608. PubMed
  4. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  5. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  6. Yan J, et al. 2020. Cancer Discov. 10:124. PubMed
  7. Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed
  8. Harel M, et al. 2020. J Immunol. 205:1167. PubMed
  9. Yu H, et al. 2020. Front Immunol. 11:1773. PubMed
  10. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  11. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  12. Liu T, et al. 2023. Cardiovasc Res. 119:1046. PubMed
  13. Bahreyni A, et al. 2023. Biomed Pharmacother. 163:114789. PubMed
  14. Bahreyni A, et al. 2023. BMC Med. 21:193. PubMed
  15. Guo R, et al. 2020. Cell Res. 30:21. PubMed
  16. Asthagiri Arunkumar G, et al. 2019. Vaccine. 37:5567. PubMed
  17. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  18. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  19. Waickman AT, et al. 2017. Cytokine. 99:266. PubMed
  20. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
  21. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  22. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  23. Yang J, et al. 2020. Front Immunol. 10:3048. PubMed
  24. de Souza RG, et al. 2021. Am J Pathol. 191:294. PubMed
  25. Haque M, et al. 2021. Viruses. 13:. PubMed
  26. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
  27. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  28. Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed
  29. Flores–Santibáñez F, et al. 2018. Front Immunol. 0.520138889. PubMed
  30. Knuschke T, et al. 2018. Front Immunol. 0.801388889. PubMed
  31. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
  32. Willimsky G, et al. 2021. Elife. 10:. PubMed
  33. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  34. Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed
  35. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  36. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  37. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  38. Hua J, et al. 2018. Sci Rep. 5.235416667. PubMed
  39. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  40. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  41. Kamdar K, et al. 2018. J Immunol. 201:230. PubMed
  42. Overacre-Delgoffe AE, et al. 2017. Cell. 169:1130. PubMed
  43. Juneja VR, et al. 2017. J Exp Med. 214:895. PubMed
  44. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  45. Tan Z, et al. 2020. Mol Ther Oncolytics. 16:302. PubMed
  46. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  47. Bittner-Eddy PD, et al. 2020. Front Immunol. 11:677. PubMed
  48. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  49. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  50. Chung YM, et al. 2021. J Immunother Cancer. 9:. PubMed
  51. Opejin A, et al. 2020. Cell Reports. 33(8):108424. PubMed
  52. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  53. Riggan L, et al. 2020. Cell Rep. 31:107651. PubMed
  54. Huang L, et al. 2021. Dev Neurobiol. 81:736. PubMed
  55. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  56. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  57. Daley D, et al. 2017. Nat Med. 23:556. PubMed
  58. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
  59. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  60. Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed
  61. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  62. Kim SJ, et al. 2020. Cell Mol Immunol. 17:728. PubMed
  63. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  64. Ranjan K, et al. 2021. J Clin Invest. 131:. PubMed
  65. Van Dis E, et al. 2022. PLoS Pathog. 18:e1010721. PubMed
  66. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
  67. Kakaradov B, et al. 2017. Nat Immunol. 18:422. PubMed
  68. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
  69. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  70. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  71. Ko S, et al. 2005. J Immunol. 175:3309. PubMed
  72. Xu G, et al. 2007. J Immunol. 179:5358. PubMed
  73. Dudek M, et al. 2021. Nature. 592:444. PubMed
  74. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  75. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  76. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
  77. Sun Y, et al. 2021. Nat Commun. 12:5147. PubMed
  78. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
  79. Uehara H, et al. 2021. eLife. 10:00. PubMed
  80. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  81. Mittal D, et al. 2017. Cancer Immunol Res. 5:1098. PubMed
  82. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
  83. Kaushik DK, et al. 2019. J Clin Invest. 130. PubMed
  84. García-Lozano A, et al. 2018. Front Microbiol. 9:1275. PubMed
  85. Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed
  86. Haring J, et al. 2008. J Immunol. 180:2855. PubMed
  87. Lee JK, et al. 2021. Cell Mol Immunol. 18:1395. PubMed
  88. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  89. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  90. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  91. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  92. Bordoloi D, et al. 2021. Genes Cancer. 12:51. PubMed
  93. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
  94. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  95. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
RRID
AB_315395 (BioLegend Cat. No. 505801)
AB_315395 (BioLegend Cat. No. 505802)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
IFN-gamma
Specificity Alt (DOES NOT SHOW ON TDS):
IFN-γ
App Abbreviation (DOES NOT SHOW ON TDS):
ELISA Capture,CyTOF®,IHC,WB
UniProt
View information about IFN-gamma on UniProt.org
Go To Top Version: 2    Revision Date: 07/16/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account